Login to Your Account



Bioverativ paying up to $825M for True North

By Michael Fitzhugh
Staff Writer

Tuesday, May 23, 2017

Biogen Inc. spin-off Bioverativ Inc. will pay $400 million up front plus assumed cash to acquire True North Therapeutics Inc., a spinout with an early stage FDA breakthrough-designated candidate for CAD.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription